American College of Clinical Pharmacy
      Search      Cart
         
  Poster Hall

Sat-31 - Observation of Opioid and Sedative Use in Mechanically Ventilated Adults: An ALERT-ICU Sub-study

Scientific Poster Session I - Encore

Encore Presentations
  Saturday, October 12, 2024
  11:30 AM–01:00 PM

Abstract

Introduction/Hypothesis

Iatrogenic withdrawal syndrome (IWS) is associated with large doses and/or prolonged use of opioids or sedatives. This study aimed to determine current patterns of opioid and sedative use in mechanically ventilated (MV) adults that may be associated with IWS. We hypothesized that many patients would receive high doses of opioids and sedatives for prolonged periods.

Methods

This was a posthoc analysis of an international, observational, point prevalence study conducted on a single date between June 1 and September 30, 2021, for invasively MV ICU patients = 18 years old. The primary outcome was the proportion of patients receiving continuous opioids or sedatives for = 72-hr, which included continuous IV infusion, scheduled injections, or as-needed parenteral doses with at least half administered within 24 hours. Outcomes were compared between patients receiving opioids or sedatives < 72 and = 72-hr. Statistical analyses were performed using IBM SPSS Statistics version 28.0.0 (Armonk, New York) according to the level of measurement, data distribution, and assumptions. The a priori alpha was 5%.

Results

There were 1066 patients enrolled in 229 ICUs at 87 hospitals in 11 countries. Median ICU stay was 7 (IQR, 3-16) days; 50% were admitted for respiratory disease, 40% had ARDS, and 37% tested positive for COVID-19. The median duration of MV was 4.6 (IQR, 1.4-11.5) days. Over half of the patients received continuous opioids (59%; 556/938) or sedatives (59%; 546/932) for = 72-hr, with most receiving continuous IV infusion opioids (91%) and sedatives (99%). Median 24-hr total opioid and sedative doses were significantly greater when used = 72-hr except for remifentanil (p=0.119), sufentanil (p=0.251), ketamine (p=0.053), and lorazepam (p=0.070). Patients on opioids or sedatives for < 72-hr received > 50% dose reductions (55% vs. 36%; p<0.001) when weaning occurred, while those on agents = 72-hr had = 20% dose reductions (31% vs. 15%; p<0.001). Three of 8 patients assessed had IWS, all receiving opioids or sedatives = 72-hr.

Conclusions

Over half of MV adult ICU patients received continuous parenteral opioids or sedatives for = 72-hr at higher total doses than those receiving opioids or sedatives for < 72-hr, which may increase the risk of IWS.

Presenting Author

Scott Bolesta PharmD, BCCCP, FCCP, FCCM
Wilkes University

Authors

Lisa Burry PharmD, PhD
Mount Sinai Hospital

Federico Carini MD
University of Toronto

Rebekah Eadie MPharm, MSc
Ulster Hospital

Brian Erstad PharmD
The University of Arizona College of Pharmacy

Celine Gelinas RN, PhD
McGill Uinversity

Marc Perreault PharmD, MSc
University of Montreal,

Richard Riker MD
Maine Medical Center

Kathryn Smith PharmD
Maine Medical Center

Cookies

This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.